Twenty-five analysts covered Gilead Sciences (GILD) in July 2017. One analyst recommended a “strong buy,” ten analysts recommended a “buy,” and 14 analysts recommended a “hold” on the stock.
To further expand the label of its transcatheter heart valve (or THV), SAPIEN 3, Edwards Lifesciences (EW) is currently involved in enrolling patients in its EARLY-TAVR trial.
Edwards Lifesciences’ (EW) SAPIEN 3 Ultra system is a next-generation platform, with expandable Axela sheath technology and on-balloon delivery design.
To expand the market for TAVR therapy, Edwards Lifesciences (EW) has developed a three-pronged strategy that involves increasing awareness, expanding indications, and deploying advanced technology.
Edwards Lifesciences (EW) estimated that in 2011, the penetration of transcatheter aortic valve replacement (or TAVR) therapy in severe symptomatic aortic stenosis (or ssAS) was ~9%.
On August 18, 2016, the FDA expanded the label of Edwards Lifesciences’ two transcatheter aortic valves—Sapien XT and Sapien 3—for patients suffering with aortic valve stenosis.
Demand for transcatheter aortic valve replacement (or TAVR) therapy has been robust in the US, mainly due to the opening of new heart valve centers and relatively lower competition.
In 2Q17, Edwards Lifesciences’ (EW) Transcatheter Heart Valve Therapy segment reported revenues close to $316 million, which represents year-over-year growth of ~28%.
Wall Street analysts have projected Edwards Lifesciences’ fiscal 2017 revenues to be close to $3.4 billion, which represents year-over-year growth of ~14.2%.
In 2Q17, Edwards Lifesciences (EW) reported revenues close to $842 million. The company reported underlying year-over-year revenue growth of ~15% in 2Q17.
On July 28, 2017, GlaxoSmithKline (GSK) traded at a forward PE multiple of 13.4x, which is slightly lower than the industry average of 15.2x.
GlaxoSmithKline (GSK) reported flat international revenues at constant exchange rates to 843.0 million pounds during 2Q17.
GSK’s Vaccines business reported 16.0% growth to ~1.1 billion pounds in 2Q17, including 5.0% growth at constant exchange rates and 11.0% positive impact of foreign exchange.
The Global Pharmaceuticals franchise reported revenues of ~3.2 billion pounds in 2Q17.
GSK’s HIV Products franchise reported growth of 29.0% to ~1.1 billion pounds in 2Q17 compared to 2Q16.
GSK’s Pharmaceuticals segment’s contribution to the company’s total revenues was 59.5% in 2Q17.
GSK reported operational growth of 3% in its revenues to ~7.3 billion pounds for 2Q17.
In its earnings release on July 26, GlaxoSmithKline (GSK) reported 12% growth to ~7.3 billion pounds in its 2Q17 revenues. GSK surpassed analysts’ estimates for revenues and earnings per share.
As of July 31, 2017, of the 22 analysts tracking Pfizer, ten recommend a “buy” for the stock, while 11 recommend a “hold,” and one recommends a “sell.”
Analysts expect a 0.5% fall in Pfizer’s (PFE) 2Q17 revenues to $13.08 billion, following a decline in revenues from blockbuster drugs including Celebrex, Zyvox, and Lyrica.